AR125196A1 - Derivados de ciclobutilo 1,3-sustituidos y sus usos - Google Patents

Derivados de ciclobutilo 1,3-sustituidos y sus usos

Info

Publication number
AR125196A1
AR125196A1 ARP220100676A ARP220100676A AR125196A1 AR 125196 A1 AR125196 A1 AR 125196A1 AR P220100676 A ARP220100676 A AR P220100676A AR P220100676 A ARP220100676 A AR P220100676A AR 125196 A1 AR125196 A1 AR 125196A1
Authority
AR
Argentina
Prior art keywords
c6alkyl
independently selected
occurrence independently
subject
nr3r4
Prior art date
Application number
ARP220100676A
Other languages
English (en)
Spanish (es)
Inventor
Donglei Liu
James J Powers
Julien Papillon
Stefan Peukert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR125196A1 publication Critical patent/AR125196A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/74Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP220100676A 2021-03-26 2022-03-22 Derivados de ciclobutilo 1,3-sustituidos y sus usos AR125196A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163166289P 2021-03-26 2021-03-26

Publications (1)

Publication Number Publication Date
AR125196A1 true AR125196A1 (es) 2023-06-21

Family

ID=80999265

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100676A AR125196A1 (es) 2021-03-26 2022-03-22 Derivados de ciclobutilo 1,3-sustituidos y sus usos

Country Status (14)

Country Link
US (2) US11845730B2 (https=)
EP (1) EP4313951A1 (https=)
JP (1) JP2024510778A (https=)
KR (1) KR20230162660A (https=)
CN (1) CN117062804A (https=)
AR (1) AR125196A1 (https=)
AU (1) AU2022244467A1 (https=)
CA (1) CA3214066A1 (https=)
IL (1) IL307189A (https=)
MX (1) MX2023011377A (https=)
PY (1) PY2221203A (https=)
TW (1) TW202304864A (https=)
UY (1) UY39681A (https=)
WO (1) WO2022201097A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR125196A1 (es) * 2021-03-26 2023-06-21 Novartis Ag Derivados de ciclobutilo 1,3-sustituidos y sus usos
WO2024062389A1 (en) * 2022-09-21 2024-03-28 Bausch + Lomb Ireland Limited Crystalline polymorph forms of a trpv1 antagonist and formulations thereof
US20240148709A1 (en) * 2022-11-08 2024-05-09 Aisa Pharma, Inc. Methods of treating eye pain and eye disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7514562B2 (en) * 2003-03-07 2009-04-07 Glaxo Group Limited Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
RU2451014C2 (ru) 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
EP2050734A1 (en) 2006-07-13 2009-04-22 Kyowa Hakko Kirin Co., Ltd. Pentadienamide derivative
NZ577980A (en) 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
WO2012072512A1 (en) * 2010-11-29 2012-06-07 Glaxo Group Limited N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists
DE102010052781A1 (de) 2010-11-30 2012-05-31 Trw Automotive Gmbh Befestigungsvorrichtung und Befestigungsbaugruppe zur Befestigung eines Gasgenerators und Fahrzeuginsassenrückhaltesystem
TW201302681A (zh) * 2011-03-25 2013-01-16 Abbott Lab Trpv1拮抗劑
JP2014510768A (ja) * 2011-04-11 2014-05-01 グラクソ グループ リミテッド Trpv1アンタゴニストとしてのn−シクロブチルイミダゾピリジンメチルアミン
US9747862B2 (en) 2015-11-02 2017-08-29 Castar, Inc. Method of immersive rendering for wide field of view
US10269906B2 (en) * 2016-11-30 2019-04-23 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device having two spacers
WO2018151678A1 (en) * 2017-02-15 2018-08-23 Agency For Science, Technology And Research Compounds for treatment of cancer and epigenetics
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
AU2019392904B9 (en) 2018-12-07 2022-12-22 University Of Maryland, Baltimore Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors
AR125196A1 (es) * 2021-03-26 2023-06-21 Novartis Ag Derivados de ciclobutilo 1,3-sustituidos y sus usos

Also Published As

Publication number Publication date
IL307189A (en) 2023-11-01
AU2022244467A1 (en) 2023-10-12
JP2024510778A (ja) 2024-03-11
EP4313951A1 (en) 2024-02-07
PY2221203A (es) 2022-11-24
UY39681A (es) 2022-10-31
US12435040B2 (en) 2025-10-07
MX2023011377A (es) 2023-10-06
US11845730B2 (en) 2023-12-19
WO2022201097A1 (en) 2022-09-29
CN117062804A (zh) 2023-11-14
BR112023019496A2 (pt) 2023-12-05
US20220324811A1 (en) 2022-10-13
US20240308965A1 (en) 2024-09-19
TW202304864A (zh) 2023-02-01
CA3214066A1 (en) 2022-09-29
KR20230162660A (ko) 2023-11-28

Similar Documents

Publication Publication Date Title
AR125196A1 (es) Derivados de ciclobutilo 1,3-sustituidos y sus usos
PE20221264A1 (es) Inhibidores de egfr
PE20070217A1 (es) Derivados de isoquinolona sustituidos con piperidinilo
PE20231185A1 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica
PE20011259A1 (es) Derivado de piridina y pirimidina
AR044514A1 (es) Acidos carboxilicos alfa sustituidos como moduladores ppar
AR032679A1 (es) Derivados del acido isoftalico como inhibidores de metaloproteinasas de la matriz
ES2180633T3 (es) Uso de derivados de pteridina como inhibidores de la no-sintasa.
ES2082639T3 (es) Derivados del indol como agonistas de los receptores similares a 5-ht1.
EA200001009A1 (ru) Производные пиридина, ингибирующие фосфодиэстеразу iv
AR033207A1 (es) Metodo de tratamiento de desordenes inflamatorios oculares y de desordenes relacionados con angiogenesis del segmento posterior del ojo usando un derivado amida de flurbiprofen o ketorolac
PE20231375A1 (es) Derivados de n-(piperidin-4-il)benzamida de accion luminal
FR889245A (fr) Procédé d'amélioration de l'amortissement des sons par les murs rigides
FR1008417A (fr) Procédé pour le traitement de fibres artificielles discontinues
FR1040338A (fr) Procédé de concentration et de récupération des hydracides
AR131840A2 (es) Derivados de pirrolopiridina y su uso en el tratamiento de una infeccion por rsv
GB586497A (en) Improvements in methods and apparatus for toughening sheets of glass
MX2025015072A (es) Agentes antipaludicos
PE20240926A1 (es) Compuestos de espirolactama y metodos para tratar infecciones virales usando los mismos
AR132628A1 (es) Compuestos derivados de feniloxazolona sustituida
PE20251887A1 (es) Derivados de piridina como inhibidores de proteina cinasas
PE20252584A1 (es) Compuestos de tetrahidropirrolo-piridinona sustituidos y su uso en el tratamiento de afecciones medicas
AR123789A1 (es) Novedosos análogos de glutamina
AR027032A1 (es) Derivados de analogos de benzimidazol sustituidos de homopiperidinilo
FR914585A (fr) Procédé de fixation des charnières sur les montures et sur les branches de lunettes